Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma

• Published in: Allergology international Vol. 66; no. 3; pp. 404 - 410
• Main Authors: Nagasaki, Tadao, Matsumoto, Hisako, Izuhara, Kenji, Kanemitsu, Yoshihiro, Tohda, Yuji, Horiguchi, Takahiko, Kita, Hideo, Tomii, Keisuke, Fujimura, Masaki, Yokoyama, Akihito, Nakano, Yasutaka, Hozawa, Soichiro, Ito, Isao, Oguma, Tsuyoshi, Izuhara, Yumi, Tajiri, Tomoko, Iwata, Toshiyuki, Yokoyama, Tetsuji, Niimi, Akio, Mishima, Michiaki
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.07.2017; Elsevier
• Subjects: Animals; Asthma; Asthma - diagnosis; Asthma - immunology; Asthma - metabolism; Asthma - therapy; Biomarkers; Breath Tests; Cell Adhesion Molecules - blood; Composite marker; Disease Management; Disease Progression; Eosinophils - immunology; Eosinophils - metabolism; Eosinophils - pathology; Exhalation; Humans; Nitric oxide; Nitric Oxide - metabolism; Prognosis; Respiratory Function Tests; Serum periostin; Type-2/eosinophilic inflammation; FeNO; Type-2/eosinophilic inflammation; IL; IgE; Serum periostin; TNF; Asthma; Composite marker; TGF; Nitric oxide; ICS; iNOS; FEV1; KiHAC
• ISSN: 1323-8930; 1440-1592; 1440-1592
• DOI: 10.1016/j.alit.2017.02.003

Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma. Therefore, efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered markers of type-2/eosinophilic inflammation in asthma. However, a single-marker approach has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-marker approach and in a multiple-marker approach in identifying patients with severe type-2/eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC), geno-endo-phenotypes of patients were stratified into four groups according to the FeNO and serum periostin levels. Frequency of asthma exacerbations over 2 years following enrollment and frequency of IL4RA rs8832GG genotype in patients belonging to the four groups stratified according to FeNO and serum periostin levels. FeNO, fractional exhaled nitric oxide. [Display omitted]